Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
<p>Abstract</p> <p>Although some patients are initially sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), resistance invariably develops. Therefore, it’s very important to study the molecular mechanism of this resistance. In our previous study we...
Main Authors: | Ju Lixia, Zhou Caicun |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2013-02-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | http://www.cancerci.com/content/13/1/15 |
Similar Items
-
Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
by: Xiaolin Ren, et al.
Published: (2024-02-01) -
Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
by: Qi Sun, et al.
Published: (2022-06-01) -
Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases
by: Meirong LIU, et al.
Published: (2019-01-01) -
Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib
by: Yinyin Xue, et al.
Published: (2025-03-01) -
Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKI
by: Juan JIANG, et al.
Published: (2015-08-01)